Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

(2014) K Kavanagh et al.   BRITISH JOURNAL OF CANCER

Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women

(2014) B. Baldur-Felskov et al.   JNCI-Journal of the National Cancer Institute

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia

(2014) E. Crowe et al.   BMJ-British Medical Journal

Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact

(2013) Kimberley Kavanagh et al.   BMC INFECTIOUS DISEASES

Achieving high and equitable coverage of adolescent HPV vaccine in Scotland

(2013) Katy Sinka et al.   JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH

Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes

(2013) Tom Glass Hopkins et al.   VACCINE

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

(2012) Talía Malagón et al.   LANCET INFECTIOUS DISEASES

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions

(2012) Suzanne E. Powell et al.   VACCINE

Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England

(2012) Harriet L. Bowyer et al.   VACCINE

Using computerised decision support to improve compliance of cancer multidisciplinary meetings with evidence-based guidance

(2012) Vivek Patkar et al.   BMJ Open

HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland

(2011) M C O'Leary et al.   BRITISH JOURNAL OF CANCER

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

(2011) Barbara Romanowski et al.   Human vaccines & immunotherapeutics

‘A False Sense of Security’? Understanding the Role of the Hpv Vaccine on Future Cervical Screening Behaviour: A Qualitative Study of Uk Parents and Girls of Vaccination Age

(2011) Lorna Henderson et al.   JOURNAL OF MEDICAL SCREENING

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

(2011) Aimée R. Kreimer et al.   JNCI-Journal of the National Cancer Institute

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

(2011) Julia ML Brotherton et al.   LANCET

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines

(2010) K Cuschieri et al.   BRITISH JOURNAL OF CANCER

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET